| scholarly article | Q13442814 |
| P50 | author | Anne Hersey | Q33035164 |
| P2093 | author name string | Brad Sherborne | |
| Ian Cooper | |||
| Yuan H Zhao | |||
| Michael H Abraham | |||
| Joelle Le | |||
| Gordon Beck | |||
| Chris N Luscombe | |||
| P2860 | cites work | Species differences in the disposition and metabolism of camazepam | Q28282309 |
| Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings | Q28842973 | ||
| Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption | Q29038267 | ||
| Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors. | Q30652076 | ||
| Effects of liver disease on pharmacokinetics. An update | Q33789233 | ||
| Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats | Q34067981 | ||
| Dose-dependent intestinal absorption and significant intestinal excretion (exsorption) of the beta-blocker pafenolol in the rat. | Q34335089 | ||
| Metabolic disposition of enciprazine, a non-benzodiazepine anxiolytic drug, in rat, dog and man | Q34550227 | ||
| Pharmacokinetics of drugs in overdose | Q35759107 | ||
| Metabolism and pharmacokinetics of nufenoxole in animals and humans: an example of stereospecific hydroxylation of an isoquinuclidine ring | Q70257909 | ||
| Excretion and metabolism of lorcainide in rats, dogs and man | Q71205847 | ||
| Absorption, distribution, metabolism, and excretion of 1,3-diphenylguanidine in the male F344 rat | Q71259275 | ||
| Drug absorption. I. An in situ rat gut technique yielding realistic absorption rates | Q71357054 | ||
| Absorption and disposition of ranitidine hydrochloride in rat and dog | Q71728610 | ||
| Correlation of drug absorption with molecular surface properties | Q71795029 | ||
| Study on the absorption of vinpocetine and apovincaminic acid | Q72035838 | ||
| Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to rats: absorption from various GI segments | Q72052577 | ||
| Metabolism and disposition of 14C-granisetron in rat, dog and man after intravenous and oral dosing | Q72122579 | ||
| Disposition and metabolism of a novel diurea inhibitor of acyl CoA: cholesterol acyltransferase (YM17E) in the rat and dog | Q72288296 | ||
| The absorption, distribution and excretion of [14C]lormetazepam in dogs, rabbits, rats and rhesus monkeys | Q72431221 | ||
| Gastrointestinal and hepatic first-pass metabolism of aspirin in rats | Q72523897 | ||
| Metabolism of Casodex in laboratory animals | Q72598178 | ||
| Metabolic disposition of 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man | Q72847659 | ||
| The metabolism of carfecillin in rat, dog and man | Q72877489 | ||
| Similarity in the linear and non-linear oral absorption of drugs between human and rat | Q73244489 | ||
| Pharmacokinetics of acetaminophen after intravenous and oral administration to spontaneously hypertensive rats and normotensive Wistar rats | Q73272586 | ||
| In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man--fact or myth | Q73482559 | ||
| Absorption and disposition of a tripeptoid and a tetrapeptide in the rat | Q77333893 | ||
| Prediction of intestinal drug absorption properties by three-dimensional solubility parameters | Q77357213 | ||
| Bimodal column switching liquid chromatographic assay of six metabolites of [14C] felodipine in rat urine | Q93648960 | ||
| The metabolism of tinidazole in the rat and dog | Q93757289 | ||
| Absorption, distribution, metabolism and excretion of 14C-labelled enantiomers of the calcium channel blocker benidipine after oral administration to rat | Q93907960 | ||
| Absorption of the β-Adrenergic-Blocking Agent, Nadolol, by Mice, Rats, Hamsters, Rabbits, Dogs, Monkeys, and Man: An Unusual Species Difference | Q39210510 | ||
| Clinical pharmacokinetics of doxorubicin | Q39513605 | ||
| Disposition and Metabolism of Atenolol in Animals | Q39603929 | ||
| Pharmacokinetics of fosmidomycin, a new phosphonic acid antibiotic | Q39856457 | ||
| Absorption and Excretion of 1-Amino-2-Naphthol-6-Sulphonic Acid in Rats and Rabbits | Q40543837 | ||
| Cyclosporin clinical pharmacokinetics | Q40918376 | ||
| Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences | Q41478162 | ||
| Pharmacokinetic changes during pregnancy and their clinical relevance | Q41657026 | ||
| Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms | Q41714891 | ||
| The fate of [14C]saccharin in man, rat and rabbit and of 2-sulphamoyl[14C]benzoic acid in the rat | Q41901274 | ||
| Metabolism of L-[guanidinooxy-14C]canavanine in the rat. | Q42215220 | ||
| Pharmacokinetics and metabolism of mespirenone, a new aldosterone antagonist, in rat and cynomolgus monkey | Q42218785 | ||
| Species differences in the metabolism and excretion of fenclofenac | Q42273856 | ||
| The disposition of the local anaesthetic, pentacaine, in rats and mice | Q42661121 | ||
| Pharmacokinetics and metabolism of fosmidomycin, a new phosphonic acid, in rats and dogs | Q42670075 | ||
| Comparison of oral absorption and bioavailablity of drugs between monkey and human | Q44074776 | ||
| Tissue distribution and excretion of amodiaquine in the rat. | Q44349730 | ||
| The metabolism of terbutaline in dog and rat. | Q44378664 | ||
| Animal pharmacokinetics of inogatran, a low-molecular-weight thrombin inhibitor with potential use as an antithrombotic drug | Q47293302 | ||
| The disposition and metabolism of I.C.I. 58,834 (viloxazine) in animals | Q48478909 | ||
| Pharmacokinetics of the stable prostacyclin analogue, nileprost, in the rat | Q48788814 | ||
| Disposition of 14C-loprazolam in animals and man. | Q48792473 | ||
| Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans. | Q51557257 | ||
| Disposition of pranolium chloride in small mammals. | Q51659551 | ||
| QSAR model for drug human oral bioavailability. | Q52076626 | ||
| Prediction of human intestinal absorption of drug compounds from molecular structure. | Q52238446 | ||
| A general approach for the prediction of the intestinal absorption of drugs: regression analysis using the physicochemical properties and drug-membrane electrostatic interaction. | Q52238684 | ||
| Diflubenzuron: intestinal absorption and metabolism in the rat. | Q52525967 | ||
| Metabolism of pamaqueside, a cholesterol absorption inhibitor, in Long-Evans rat: effect of bile duct cannulation on absorption. | Q53921649 | ||
| The metabolic disposition of acifran, a new antihyperlipidemic agent, in rats and dogs. | Q54147515 | ||
| Pharmacokinetics and pharmacodynamics of bromocriptine in the rat. | Q54206542 | ||
| The excretion of (35S)dapsone and its metabolites in the urine, faeces and bile of the rat. | Q54367466 | ||
| Absorption, distribution and excretion of sultopride in man and several animal species. | Q54470762 | ||
| Studies on Absorption of Drugs. VIII. Physicochemical Factors affecting the Absorption of Sulfonamides from the Rat Small Intestine | Q54736590 | ||
| Polar molecular surface properties predict the intestinal absorption of drugs in humans. | Q55067034 | ||
| The Metabolic Fate of Prazosin | Q67066721 | ||
| The Disposition of Doxycycline by the Rat | Q67278599 | ||
| Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man | Q67585777 | ||
| Metabolism of toremifene in the rat | Q68422082 | ||
| Effects of biliary excretion on the disposition of felodipine and metabolites in the rat | Q68526562 | ||
| Absorption, distribution and excretion of nilvadipine, a new dihydropyridine calcium antagonist, in rats and dogs | Q68551592 | ||
| Absorption, distribution and excretion of lacidipine, a dihydropyridine calcium antagonist, in rat and dog | Q68571564 | ||
| Interspecies comparison of the metabolic pathways of perindopril, a new angiotensin-converting enzyme (ACE) inhibitor | Q68571569 | ||
| Disposition and metabolism of [14-14C] 4-demethoxydaunorubicin HCl (idarubicin) and [14-14C]daunorubicin HCl in the rat. A comparative study | Q68719760 | ||
| Absorption of iothalamate after oral administration and absorption enhancement by amino acids in dogs and rats | Q68978117 | ||
| Pharmacokinetics of bromerguride, a new dopamine-antagonistic ergot derivative in rat and dog | Q69128404 | ||
| Studies on Sulfamethoxazole/Trimethoprim. Absorption, Distribution, Excretion and Metabolism of Trimethoprim in Rat | Q69410050 | ||
| Pharmacokinetics and metabolism of omeprazole in animals and man--an overview | Q69838804 | ||
| Metabolism of amlodipine in the rat and the dog: a species difference | Q70055330 | ||
| P433 | issue | 3 | |
| P921 | main subject | absorption | Q332828 |
| P304 | page(s) | 233-243 | |
| P577 | publication date | 2003-03-01 | |
| P1433 | published in | European Journal of Medicinal Chemistry | Q3008624 |
| P1476 | title | Evaluation of rat intestinal absorption data and correlation with human intestinal absorption | |
| P478 | volume | 38 |
| Q31159063 | A comparative evaluation of models to predict human intestinal metabolism from nonclinical data |
| Q35989176 | A concise review of applications of micellar liquid chromatography to study biologically active compounds |
| Q45978265 | Cefuroxime axetil solid dispersion with polyglycolized glycerides for improved stability and bioavailability. |
| Q45263024 | Comparison of intestinal metabolism of CYP3A substrates between rats and humans: application of portal-systemic concentration difference method |
| Q79738795 | Development of an in vitro rat intestine segmental perfusion model to investigate permeability and predict oral fraction absorbed |
| Q30372564 | Dietary modulation and structure prediction of rat mucosal pentraxin (Mptx) protein and loss of function in humans |
| Q36885229 | Evaluation and suggested improvements of the Biopharmaceutics Classification System (BCS). |
| Q38730618 | Explication of Definitional Description and Empirical Use of Fraction of Orally Administered Drugs Absorbed From the Intestine (Fa) and Intestinal Availability (Fg): Effect of P-glycoprotein and CYP3A on Fa and Fg. |
| Q39895437 | Fasting increases tobramycin oral absorption in mice |
| Q83387798 | Improved bioavailability of orally administered andrographolide from pH-sensitive nanoparticles |
| Q42680392 | Interspecies modeling and prediction of human exenatide pharmacokinetics |
| Q36050847 | Mucosal and blood-brain barrier transport kinetics of the plant N-alkylamide spilanthol using in vitro and in vivo models. |
| Q44738634 | Preclinical pharmacokinetics and metabolism of a potent non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase |
| Q26764739 | Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models |
| Q36885247 | Prediction of human pharmacokinetics--gastrointestinal absorption |
| Q37139856 | Prediction of human pharmacokinetics-biliary and intestinal clearance and enterohepatic circulation |
| Q38177366 | Pros and cons of methods used for the prediction of oral drug absorption. |
| Q46977325 | Rat poorly predicts the combined non-absorbed and presystemically metabolized fractions in the human |
| Q46790745 | Relationship between lethal toxicity in oral administration and injection to mice: effect of exposure routes |
| Q36231000 | Skin-mimetic chromatography for prediction of human percutaneous absorption of biologically active compounds occurring in medicinal plant extracts |
| Q46717300 | Stabilization and improved in vivo performance of amorphous etoricoxib using Gelucire 50/13. |
| Q30670381 | The use of ROC analysis for the qualitative prediction of human oral bioavailability from animal data. |
| Q36535786 | Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. |
Search more.